ProBio News
-
ProBio Enters Exclusive Global Licensing Agreement with AbTis To Develop Next-Generation ADC Asset
11/10/2026
ProBio, a global contract research, development, and manufacturing organization (CRDMO), today announced that it has entered into an exclusive global licensing agreement with AbTis Co., Ltd., a South Korean biotechnology company and subsidiary of Dong-A ST, specializing in site-specific conjugation technologies for antibody-drug conjugates (ADCs).
-
ProBio Successfully Completes NMPA Pre-Approval Inspection For Biologics Manufacturing Facility In Nanjing, China
11/4/2026
ProBio Inc., a global contract research, development and manufacturing organization (CRDMO), today announced the successful completion of a Pre-Approval Inspection (PAI) by China's National Medical Products Administration (NMPA) at its biologics manufacturing facility in Nanjing, China, marking an important milestone in the company's continued expansion of its biologics GMP manufacturing capabilities and regulatory readiness.
-
ProBio's AAV Manufacturing Excellence Powers UC Irvine And GlyTR Therapeutics First‑In‑Class Pan-Cancer CAR‑T Program
11/4/2026
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell platform, GlyTR (pronounced 'glitter'), engineered to target tumor‑associated carbohydrate antigens that are highly expressed across a broad range of cancers. Unlike traditional high‑affinity antibody based CAR designs, GlyTR uses a unique "velcro‑like" lectin binding mechanism that enables selective elimination of cancer cells while minimizing off‑tumor toxicity and expanding the potential of CAR‑T therapy into solid tumors where safety has historically been a major barrier.
-
ProBio And GCP ClinPlus Partner To Accelerate Clinical Trials In China
11/4/2026
ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development solutions for global biopharma customers.
-
ProBio De-Risks Cell & Gene Therapy With New Packaging Test
11/4/2026
To address the critical need for accelerated decision-making and de-risked progression from discovery to Chemistry, Manufacturing, and Controls (CMC) in cell and gene therapy programs, ProBio Inc. has launched its new Viral Vector Packaging Test. This early-stage development offering provides biopharma innovators with essential data and technical confidence, strengthening ProBio's end-to-end capabilities in advanced therapies.
-
ProBio And Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO Solutions For Advanced Therapies
9/16/2026
ProBio, a leading global contract development and manufacturing organization (CDMO) focused on biologics and cell and gene therapies (CGT), today announced a strategic collaboration with Kun Tuo, an IQVIA company and leading clinical research organization (CRO) in China.
-
ProBio And Curocell Achieve Key CAR-T Milestone With BLA Regulatory Approval And Commercial Readiness
5/11/2026
Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and Curocell have achieved a significant milestone with the BLA regulatory approval and commercial readiness of Anbalcabtagene autoleucel (Anbal-cel; code: CRC01).